Zoetis launches Vanguard CIV H3N2/H3N8 vaccine for canine influenzaDecember 12, 2017Zoetis' Vanguard CIV H3N2/H3N8 is a new bivalent vaccine helps protect dogs against CIV H3N2 and CIV H3N8, which have caused serious disease outbreaks in 38 states across the US.1 In an efficacy study, dogs that received the Vanguard CIV H3N2/H3N8 vaccine were protected from disease after CIV H3N2 challenge.2,3,4 Vaccination also appeared to help decrease the number of days after challenge that dogs shed CIV H3N2 virus—from an average of 4.9 days in the placebo-vaccinated controls to an average of 1.3 days in Vanguard CIV H3N2/H3N8 vaccinates.2,5,6 During a safety study that involved 364 dogs, including 164 client-owned dogs and 200 dogs from commercial breeding facilities, 725 doses of vaccine were administered and no significant adverse events were observed.7 Dogs that frequently are in the company of others could benefit from the protection Vanguard CIV H3N2/H3N8 offers, said Stephan Carey, DVM, Ph.D., DACVIM, assistant professor, Small Animal Clinical Sciences at Michigan State University College of Veterinary Medicine, and past president of The Veterinary Comparative Respiratory Society, and Zoetis consultant. "Dogs that attend day care, visit the dog park, or stay at boarding facilities are all at risk for contracting either strain of CIV," he said. …
SPONSORED CONTENTSwitch to Triple Protection in One Monthly DoseSee the difference of triple protection with the one monthly chew. + Learn More
